Cargando…
Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom
BACKGROUND: To date, reliable and comprehensive health-related quality of life data for patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) have not been collected in clinical trials of the disease, and no utility studies have been published. The purpose of this study...
Autores principales: | Aristides, Mike, Barlev, Arie, Barber, Beth, Gijsen, Merel, Quinn, Casey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647711/ https://www.ncbi.nlm.nih.gov/pubmed/26573610 http://dx.doi.org/10.1186/s12955-015-0377-3 |
Ejemplares similares
-
Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
por: Barlev, Arie, et al.
Publicado: (2016) -
Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study
por: Bassan, Renato, et al.
Publicado: (2019) -
Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians
por: Saltman, Deborah, et al.
Publicado: (2015) -
Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018) -
Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)